Emerging biopharma companies are rapidly adopting agentic AI to automate workflows and connect decision-making across regulated environments. Industry discussions involving ZS and SynOx Therapeutics highlight this accelerating shift. However, experts warn that many organizations still lack validated infrastructure, strong data
